

SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 1/22/19

Therapeutic Area	Therapeutic Area	Therapeutic Area	U.S. Development Stage	E.U. Development Stage
Metabolism	INVOKANA® (canagliflozin)	Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts (2)	Filed 12/18	
		Reduce the risk of MACE in patients with coronary or Peripheral Artery Disease (2)	Approved 10/18	
Immunology	aprocitentan	VTE prophylaxis in ambulatory cancer patients receiving chemo at high-risk for VTE (2)	Phase III	
		Infrainguinal revascular (2)	Phase III	
Immunology	TREMIFYA® (guselkumab)	Pediatric VTE (2)	Phase III	
		Diabetic Nephropathy (2)	Phase III	
Immunology	SIMPONI ARIA® (golimumab)	Reduce the composite risk of CV death, MI or stroke in type 2 diabetes with established, or risk for, cardiovascular disease. (CANVAS /CANVAS-R) (2)	Approved 10/18	Phase III Approved 9/18
		Resistant Hypertension (2)	Phase III	Phase III
Immunology	STELARA® (ustekinumab)	Psoriatic arthritis	Phase III	Phase III
		Psoriasis Patient-Controlled Injector	Filed 3/18	Approved 7/18
Immunology	SIMPONI ARIA® (golimumab)	Crohn's Disease	Phase III	Phase III
		Pediatric Psoriasis	Phase III	Phase III
Immunology	STELARA® (ustekinumab)	Juvenile Idiopathic Arthritis (JIA)	Phase III	Phase III
		Pediatric Psoriasis (6-12 year olds)	Phase III	Phase III
Immunology	STELARA® (ustekinumab)	Ulcerative Colitis	Filed 12/18	Filed 12/18
		Lupus	Phase III	Phase III
Infectious Diseases and Vaccines	Rilpivirine Long Acting nanosuspension for injection	HIV Infection	Phase III	Phase III
Neuroscience	pimodivir (JNJ-3872)	Influenza A (2)	Phase III	Phase III
		Treatment-resistant depression	Filed 9/18	Filed 10/18
Neuroscience	esketamine	Major depressive disorder at imminent risk for suicide	Phase III	Phase III
		Relapsing multiple sclerosis	Phase III	Phase III
Neuroscience	paliperidone palmitate 6 month long-acting injectable	Treatment of Schizophrenia	Phase III	Phase III
			Phase III	Phase III
Oncology	DARZALEX®	Frontline multiple myeloma transplant eligible in combination with bortezomib, thalidomide and dexamethasone (MMY 3006, CASSOPEIA) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY3008, MAIA) (2)	Phase III	Phase III
Oncology	DARZALEX®	Relapsed Refractory MM 1+ prior lines w/PomDex (2)	Phase III	Phase III
		Relapsed Refractory multiple myeloma w/carfilzomib/dex (Amgen sponsored) (2)	Phase III	Phase III
Oncology	DARZALEX®	Amyloidosis (AMY 3001) (2)	Phase III	Phase III
		Subcutaneous Formulation in patients with relapsed or refractory multiple myeloma (MMY3012, COLUMBA) (2)	Phase III	Phase III
Oncology	IMBRUVICA® (ibrutinib)	Smoldering multiple myeloma (SMM3001) (2)	Phase III	Phase III
		DARZALEX ® frontline multiple myeloma transplant ineligible in combination w/ bortezomib, lenalidomide and dexamethasone vs bortezomib, lenalidomide and dexamethasone (MMY3019) (2)	Phase III	Phase III
Oncology	IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
		Relapsed/refractory patients with Indolant Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III
Oncology	IMBRUVICA® (ibrutinib)	Previously untreated and relapsed/refractory patients with Waldenstrom's Macroglobulinemia in combination with Rituximab (PCYC-1127) (2)	Approved 8/18	Filed 11/18
		Frontline Chronic Lymphocytic Leukemia (Young and Fit) (in combination with Rituximab) (ECOG 1912) (2)	Phase III	Phase III
Oncology	ERLEADA™ (apalutamide)	Frontline Chronic Lymphocytic Leukemia in combination with obinutuzumab (PCYC-1130) (2)	Filed 8/18	Filed 11/18
		Frontline Chronic Lymphocytic Leukemia IV fixed duration (CLL-3011) (2)	Phase III	Phase III
Oncology	ERLEADA™ (apalutamide)	Frontline Chronic graft-versus-host-disease (cGVHD) (2)	Phase III	Phase III
		Relapsed/refractory patients with Mantle Cell Lymphoma (MCL) in combination with venetoclax (2)	Phase III	Phase III
Oncology	ERLEADA™ (apalutamide)	Relapsed/refractory patients with Mantle Cell Lymphoma in combination with venetoclax (PCYC-1143) (2)	Phase III	Phase III
		Prostate cancer non-metastatic castration-resistant	Approved 02/18	Approved 01/19
Oncology	apalutamide/ abiraterone acetate	Metastatic hormone sensitive prostate cancer	Phase III	Phase III
		Localized prostate cancer	Phase III	Phase III
Oncology	apalutamide/ abiraterone acetate	Prostate Cancer metastatic castration resistant chemotherapy naïve	Phase III	Phase III
			Phase III	Phase III
Pulmonary Hypertension	OPSUMIT®	Urothelial cancer (2)	Filed 9/18	Phase III
		Fontan-palliated in adolescent (>12 years old) and adult patients	Phase III	Phase III
Pulmonary Hypertension	UPTRAVI® IV	Pediatric pulmonary arterial hypertension	Phase III	Phase III
		Chronic thromboembolic pulmonary hypertension	Complete Response 1/19	Filed 8/18
Pulmonary Hypertension	UPTRAVI® IV	Pulmonary arterial hypertension	Phase III	Phase III

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; EDURANT STR developed in collaboration with ViiV Healthcare; aprocitentan developed in collaboration with Idorsia;

XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company

Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Erdafitinib discovered in collaboration with Astex Pharmaceuticals, Inc.;

Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
 Selective Highlights as of January 22, 2019

NMEs APPROVED 2018/2019	NMEs IN REGISTRATION	NME PLANNED FILINGS 2019-2021*	
Oncology	Oncology	Oncology	Neuroscience
<p align="center">ERLEADA™ (apalutamide) Non-metastatic prostate cancer</p>	<p align="center">Erdafitinib (FGFRI kinase inhibitor) (US) Urothelial cancer</p>	<p align="center">Niraparib Metastatic castration-resistant prostate cancer (mCRPC)</p> <p align="center">BCMA CAR-T Multiple Myeloma</p> <p align="center">Erdafitinib (FGFRI kinase inhibitor) (EU) Urothelial cancer</p>	<p align="center">Ponesimod Relapsing multiple sclerosis</p>
	<p align="center">Neuroscience</p>		<p align="center">Infectious Diseases & Vaccines</p>
	<p align="center">Esketamine Treatment resistant depression</p>		<p align="center">Pimodivir Influenza A</p>

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; Erdafitinib discovered in collaboration with Astex Pharmaceuticals, Inc.; CAR-T licensed from Legend Biotech

